Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Healthcare Company (ACHC) Asset Writedowns and Impairment (2018 - 2025)

Acadia Healthcare Company (ACHC) has disclosed Asset Writedowns and Impairment for 8 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • On a quarterly basis, Asset Writedowns and Impairment rose 17201.7% to $1.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.0 billion, a 5474.61% increase, with the full-year FY2025 number at $1.0 billion, up 5734.06% from a year prior.
  • Asset Writedowns and Impairment was $1.0 billion for Q4 2025 at Acadia Healthcare Company, up from $1.5 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $1.0 billion in Q4 2025 to a low of $1.0 million in Q2 2024.
  • A 4-year average of $117.7 million and a median of $5.8 million in 2024 define the central range for Asset Writedowns and Impairment.
  • Peak YoY movement for Asset Writedowns and Impairment: plummeted 88.5% in 2024, then soared 17201.7% in 2025.
  • Acadia Healthcare Company's Asset Writedowns and Impairment stood at $1.1 million in 2021, then increased by 1.58% to $1.1 million in 2023, then surged by 430.75% to $5.8 million in 2024, then skyrocketed by 17201.7% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for ACHC's Asset Writedowns and Impairment are $1.0 billion (Q4 2025), $1.5 million (Q2 2025), and $5.8 million (Q4 2024).